CNSP - CIK 0001729427
The table below shows CNS Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $9.77M | $9.29M | $14.10M | $9.30M | $9.81M | $5.06M |
| SG&A | $6.21M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $5.61M |
| $4.77M |
| $5.97M |
| $4.68M |
| $4.39M |
| Operating income | -$15.99M | -$14.90M | -$18.87M | -$15.27M | -$14.49M | -$9.45M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$15.85M | -$14.86M | -$18.85M | -$15.27M | -$14.50M | -$9.46M |
| EPS (diluted) | -$35.75 | -$466.89 | -$12.51K | -$11.22 | -$16.50 | - |